|
시장보고서
상품코드
2091749
0골다공증 치료 시장 규모, 점유율 및 성장 분석 : 약제 클래스별, 성별별, 투여 경로별, 유통경로별, 지역별 - 업계 예측(2026-2033년)Osteoporosis Treatment Market Size, Share, and Growth Analysis, By Drug Class (Bisphosphonates, Denosumab), By Gender (Female, Male), By Route, By Distribution, By Region - Industry Forecast 2026-2033 |
||||||
세계의 골다공증 치료 시장 규모는 2024년에 145억 2,000만 달러로 평가되며, 2025년 154억 1,000만 달러에서 2033년까지 248억 5,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 6.12%로 성장할 것으로 전망되고 있습니다.
전 세계 골다공증 치료 시장에는 골밀도 감소를 방지하고 골절 위험을 줄이는 데 중점을 둔 다양한 의약품, 생물제제 및 의료기기가 포함됩니다. 전 세계 수백만 명이 영향을 받고 있는 고령화 추세를 배경으로, 효과적인 치료법에 대한 수요가 높아지고 있습니다. 평균 수명의 연장에 따른 인구 동향의 변화는 특히 골밀도가 낮아진 여성이나 고령 남성에게 영향을 미치고 있으며, 이에 따라 보험사와 의료 서비스 제공자들이 예방 조치를 마련하도록 촉구하고 있습니다. 시장의 변천사를 살펴보면, 단순한 보충제에서 비스포스포네이트나 모노클로널 항체를 포함한 첨단 치료법에 이르기까지 역사적인 발전을 엿볼 수 있습니다. 또한 보험 환급 모델은 골절 감소에 대한 입증된 효과와 연계되는 경향이 점점 더 강해지고 있으며, 제조사들은 비용 절감 효과를 입증하는 조사에 투자해야 하는 압박을 받고 있습니다. 진단과 치료를 통합하고, 맞춤형 접근 방식을 촉진하며, 복약 순응도를 높이는 동시에 장기적인 비용을 관리하는 기업에게는 비즈니스 기회가 열리고 있습니다.
세계 골다공증 치료 시장의 성장 요인
골다공증 유병률의 증가는 고령화의 영향을 크게 받고 있으며, 그 결과 골절 위험이 높은 사람들의 수가 증가하고 있습니다. 골밀도가 감소함에 따라 환자와 의료 서비스 제공자 모두 예방 및 치료 방안을 적극적으로 모색하고 있으며, 이에 따라 승인된 치료법에 대한 수요가 증가하고 있습니다. 이 질환이 삶의 질에 미치는 부정적인 영향에 대한 인식이 높아짐에 따라 조기 진단과 지속적인 복약 순응이 촉진되고 있으며, 이는 결과적으로 제네릭 의약품과 혁신적인 제품 모두의 시장 활동을 활성화시키고 있습니다. 또한 사회 고령화가 진행되고 의료제도에 대한 재정적 압박이 커짐에 따라 뼈 헬스케어를 강화하고 치료 접근성을 개선하기 위한 정책 조치를 요구하는 움직임도 거세지고 있으며, 이는 시장 확대를 더욱 지원하고 있습니다.
세계 골다공증 치료 시장의 제약 요인
혁신적인 골다공증 치료에 수반되는 막대한 비용은, 특히 보험 적용 범위가 불충분한 지역에서 환자와 의료 시스템 모두에게 큰 장벽이 되고 있습니다. 치료비가 ‘부담 가능한’ 수준을 초과하면, 의료 종사자들은 이러한 첨단 치료법의 처방을 주저하고, 대신 효과가 낮을 가능성이 있는 구식 대체요법을 선택하기도 하는데, 이것이 새로운 치료법의 보급을 저해하고 있습니다. 또한 승인까지 걸리는 기간이 길어지거나 보험 적용 방침이 일관되지 않는 등, 보험 환급과 관련된 복잡한 사정들이 치료를 원하는 환자들에게 불확실성을 가중시키고 있습니다. 그 결과, 지불 주체와 환자 양측의 비용에 대한 민감성이 수요를 억제하고 있으며, 이러한 새로운 치료법이 가져다주는 임상적 이점에도 불구하고 시장 성장을 저해하고 있습니다.
세계 골다공증 치료 시장의 동향
전 세계 골다공증 치료 시장에서는 맞춤형 치료로 향하는 뚜렷한 추세가 나타나고 있습니다. 의료 종사자들은 개별 환자의 골대사 프로파일에 따라 약물 선택과 투여량을 최적화하기 위해 유전자형에 기반한 치료 방식을 점점 더 많이 채택하고 있습니다. 이러한 접근 방식은 치료 효과를 높일 뿐만 아니라, 부작용을 최소화하며, 지속적으로 발전하는 환자 중심 치료 모델과도 부합합니다. 제약 기업의 혁신가들은 임상시험 설계에 바이오마커를 적극적으로 도입하여, 특정 위험 표현형에 대응하는 차세대 신약 개발을 가속화하고 있습니다. 그 결과, 보험사들은 정밀 의학에 기반한 성과를 보여주는 치료법을 점점 더 중시하게 되었으며, 시장은 다양한 환자층에 보다 적절히 대응하고 장기적인 건강 결과를 개선하는 맞춤형 골다공증 치료 솔루션으로 전환되고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 골다공증 치료 시장 규모 : 약제 클래스별
세계의 골다공증 치료 시장 규모 : 성별
세계의 골다공증 치료 시장 규모 : 경로별
세계의 골다공증 치료 시장 규모 : 유통별
세계의 골다공증 치료 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.07.22Global Osteoporosis Treatment Market size was valued at USD 14.52 Billion in 2024 and is poised to grow from USD 15.41 Billion in 2025 to USD 24.85 Billion by 2033, growing at a CAGR of 6.12% during the forecast period (2026-2033).
The Global Osteoporosis Treatment Market encompasses a range of pharmaceuticals, biologics, and medical devices focused on preventing bone loss and reducing fracture risks. Driven by a growing aging population, with millions affected globally, there is an increasing demand for effective treatment options. The demographic shift towards higher life expectancy particularly affects women and older men with declining bone density, encouraging insurers and healthcare providers to implement preventive measures. Market evolution showcases a historical progression from simple supplements to sophisticated therapies, including bisphosphonates and monoclonal antibodies. Additionally, reimbursement models are increasingly tied to demonstrated effectiveness in reducing fractures, prompting manufacturers to invest in research showcasing cost savings. Opportunities arise for companies integrating diagnostics with treatment, facilitating personalized approaches and enhancing adherence while managing long-term costs.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Osteoporosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Osteoporosis Treatment Market Segments Analysis
Global osteoporosis treatment market is segmented by drug class, gender, route, distribution and region. Based on drug class, the market is segmented into Bisphosphonates, Denosumab, Teriparatide, SERMs and Romosozumab. Based on gender, the market is segmented into Female and Male. Based on route, the market is segmented into Oral, Injectable and Intravenous. Based on distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Osteoporosis Treatment Market
The rising prevalence of osteoporosis is significantly influenced by an aging population, which results in a higher number of individuals susceptible to fractures. As bone density diminishes, both patients and healthcare providers actively pursue preventive and therapeutic solutions, thereby increasing the demand for approved treatment options. Heightened awareness about the disease's detrimental effects on quality of life encourages early diagnosis and consistent medication adherence, subsequently stimulating activity within the market for both generic and innovative products. Furthermore, as societies age and financial pressures on healthcare systems grow, there is a corresponding push for policy measures that enhance bone health management and improve treatment accessibility, further bolstering market expansion.
Restraints in the Global Osteoporosis Treatment Market
The substantial expense associated with innovative osteoporosis therapies represents a considerable obstacle for both patients and healthcare systems, especially in regions where insurance coverage is inadequate. When the costs of treatment surpass what is deemed affordable, healthcare providers may hesitate to prescribe these advanced options, opting instead for older and potentially less effective alternatives, which hinders the acceptance of new therapies. Additionally, the intricacies of reimbursement, including prolonged approval times and inconsistent coverage policies, add to the uncertainty for patients seeking treatment. As a result, the sensitivity to costs among both payers and patients restricts demand, impeding market growth despite the clinical advantages provided by these novel treatments.
Market Trends of the Global Osteoporosis Treatment Market
The Global Osteoporosis Treatment market is witnessing a significant trend towards personalized therapeutics, where healthcare providers are increasingly adopting genotype-guided treatment pathways to customize drug choices and dosing based on individual bone metabolism profiles. This approach not only enhances therapeutic effectiveness but also minimizes adverse events, aligning with evolving patient-centric care models. Pharmaceutical innovators are actively integrating biomarkers into clinical trial designs, speeding up the development of next-generation agents that address specific risk phenotypes. As a result, payers are increasingly favoring therapies that showcase precision-driven outcomes, leading to a market shift toward tailored osteoporosis solutions that better serve diverse patient segments and improve long-term health outcomes.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Osteoporosis Treatment Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Bisphosphonates
- Denosumab
- Teriparatide
- SERMs
- Romosozumab
Global Osteoporosis Treatment Market Size by Gender & CAGR (2026-2033)
- Market Overview
- Female
- Male
Global Osteoporosis Treatment Market Size by Route & CAGR (2026-2033)
- Market Overview
- Oral
- Injectable
- Intravenous
Global Osteoporosis Treatment Market Size by Distribution & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online
Global Osteoporosis Treatment Market Size & CAGR (2026-2033)
- North America (Drug Class, Gender, Route, Distribution)
- US
- Canada
- Europe (Drug Class, Gender, Route, Distribution)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Gender, Route, Distribution)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Gender, Route, Distribution)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Gender, Route, Distribution)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Amgen Inc. (Prolia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- UCB SA (Evenity)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly (Forteo)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Radius Health (Abaloparatide)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Servier Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Warner Chilcott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shire (Takeda)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Chugai Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kyowa Kirin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gedeon Richter
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan (Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
